Business Wire

Headspace Health Announces Acquisition of AI-Driven Mental Health and Wellness Company, Sayana

12.1.2022 16:50:00 EET | Business Wire | Press release

Share

Headspace Health, the provider of the world’s most accessible, comprehensive digital mental health platform, today announced the acquisition of Sayana, an AI-driven mental health and wellness company. Sayana will expand Headspace Health’s ability to provide personalized self-care content to its growing global member base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005244/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Headspace Health announces acquisition of AI-driven mental health and wellness company, Sayana.

Founded in 2018 and backed by Y Combinator in 2020, Sayana has supported users around the world to improve their mental wellness by helping its members become more mindful of the connections between their feelings and events. The Sayana Self-Care app leverages chat-based sessions with an AI persona named Sayana, who encourages users to track their mood along with what influences it. Sayana personalizes users’ experiences based on their check-ins and mood trends, surfacing high-quality content and self-care exercises rooted in cognitive behavioral therapy (CBT), acceptance commitment therapy (ACT) and dialectical behavioral therapy (DBT), as well as breathing exercises. In addition, the Sayana Sleep app helps members to enjoy deep and restful sleep sessions sequenced based on their mood and sleep patterns.

“Amidst a rapidly growing landscape of mental health and wellness apps, Sayana has developed a uniquely engaging member experience backed by world-class AI and machine learning algorithms,” said Russell Glass, CEO, Headspace Health. “Sayana's technology, and most importantly, Sayana’s team, will help us meaningfully advance our product and content strategy as we continue to build the world’s most comprehensive mental health and wellbeing platform.”

On the heels of its recent merger between Headspace and Ginger, Headspace Health is creating an integrated experience to tackle the full spectrum of mental health needs - from prevention to clinical care - all from one platform backed by AI and data science. Today, Ginger leverages AI to support its team of behavioral health coaches, therapists and psychiatrists to ensure quality interactions with members, comprehensive tracking of services, and close collaboration among care providers. Headspace harnesses the power of AI to surface and recommend content in order to foster healthy habit formation. With the addition of Sayana, Headspace Health will advance its capability to personalize member experiences - to better understand, support and improve their feelings and mood.

Sayana founder and CEO Sergey Fayfer will join Headspace Health and take on a product leadership role, along with an experienced team of engineers and designers who will further advance the company’s unique and engaging member experiences.

“Since our inception, we’ve been on a mission at Sayana to put self-care in everyone’s pocket,” said Sergey Fayfer, Founder and CEO of Sayana. “We’re thrilled to bring together our technology, engineering and design expertise to help advance Headspace Health’s efforts to democratize high-quality, affordable mental healthcare around the world.”

The terms of the deal were not disclosed.

About Headspace Health

Headspace Health is the world’s leading provider of mental health and wellbeing solutions. Through our flagship Headspace brand, we’ve touched the lives of over 100 million people in 190 countries through mindfulness tools for managing stress, sleep, and focus. Our enterprise brands, Headspace for Work and Ginger, are distributed through over 3,500 enterprises, including Starbucks, Adobe, Delta Air Lines, and ViacomCBS; and through health plans such as Cigna. Our members and enterprise partners’ employees have access to mindfulness and meditation tools, CBT, coaching, therapy, and psychiatry, ultimately helping them to be healthier and more productive. To learn more about Headspace Health and our family of brands, visit www.headspacehealth.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Victoria Barnes
Sr. Director, Global Communications & Corporate Marketing, Headspace Health
781 249 3738
press@headspacehealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye